Evidence map›Paper›PMID 40476276›Full record

ArticleCochrane evidence synthesis and methods2023

What tool do undergraduate pharmacy students prefer when grading systematic review evidence: AMSTAR-2 or ROBIS?

Shaun W H Lee

Abstract read
In one paragraph

Article in Cochrane evidence synthesis and methods, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Shaun W H LeeSchool of Pharmacy Monash University Malaysia Subang Selangor Malaysia.ORCID 0000-0001-7361-6576

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: While systematic reviews (SRs) are considered the highest form of evidence in the hierarchy, the quality and standard of reviews varies. Two quality assessment tools have been developed to assess the variation in such standards. This study compared the preference, validity, reliability, and applicability of using A Measurement Tool to Assess Systematic Reviews (AMSTAR-2) and the Risk of Bias in Systematic Reviews (ROBIS) for critically appraising evidence by pharmacy students. Materials and Methods: Students attended eight lectures on evidence-based medicine. Students independently assessed two SRs using AMSTAR-2 and ROBIS. The agreement between both tools were calculated using Spearman's test while interrater reliability was calculated using Fleiss' Results: Students reported a preference for the AMSTAR-2 tool due to its clear and distinct rating criteria as well as guidance provided by the tool's developer. In comparison, students found the items on the ROBIS tool difficult to judge as it was subjective. A moderate agreement between both tools on the overall domain ratings was noted (Spearman Conclusion: The AMSTAR-2 tool had a low level of concordance in ratings of review among students. However, the AMSTAR-2 tool was preferred by students due to the clear guidance and ease of use.

Indexed as

AMSTAR‐2gradingrisk of biasROBISsystematic reviewsteaching

Identifiers

PMID40476276
PMCPMC11795889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.